Horizon scan: multiple myeloma treatment landscape

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the changing treatment landscape of multiple myeloma. Prof. Cerchione outlines novel therapies including monoclonal antibodies, proteasome inhibitors, chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engager therapies (BiTEs). In particular, Prof. Cerchione highlights promising real-world data on monoclonal antibody therapies in the front-line setting and lenalidomide maintenance therapy for multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.